Perinatal immunomodulation

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 11, Issue 5, 2002, Pages 290-301

  Patole, S ^a   Vijayakumar, P ^a   Jog, S ^a  

^a TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Fetal; Immunomodulation; Immunotherapy; Neonate; Perinatal

Indexed keywords

CROMOGLYCATE DISODIUM; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; METHYLENE BLUE; NALOXONE; PENTOXIFYLLINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTILIPOPOLYSACCHARIDE ANTIBODIES; HEMOPOIETIC GROWTH FACTOR; IMMUNOLOGICAL ADJUVANT; RHESUS D ANTIBODY;

BREAST MILK; CHRONIC LUNG DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN MORTALITY; PERINATAL CARE; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; SEPTICEMIA; CHRONIC DISEASE; FEMALE; IMMUNOLOGY; LUNG DISEASE; NEUTROPHIL; NEWBORN DISEASE; PHYSIOLOGY; PREGNANCY; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; CHRONIC DISEASE; CROMOLYN SODIUM; FEMALE; GLUCOCORTICOIDS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LUNG DISEASES; METHYLENE BLUE; MILK, HUMAN; NEUTROPHILS; PENTOXIFYLLINE; PREGNANCY; RHO(D) IMMUNE GLOBULIN; SEPSIS;

EID: 0036022651     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.11.5.290.301     Document Type: Review

References (160)

1. Immunopharmacology: Immunomodulation and immunotherapy
2. Immunology of the fetus and newborn
3. Neonatal sepsis: The potential for immunotherapy
4. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early onset sepsis
5. A new variant of Creutzfeldt-Jakob disease: The risk of transmission by blood transfusion
6. IgM enriched intravenous immunoglobulin therapy in neonatal sepsis
7. Novel approaches to the prevention and therapy of neonatal bacterial sepsis
8. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants
9. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G
10. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates
11. Antenatal diagnosis and management of fetomaternal alloimmune thrombocytopenia
12. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura
13. Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia
14. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia
15. al) on human vascular smooth muscle cells and foreskin fibroblasts: A study on normal individuals and a patient with Glanzmann's thrombasthenia
16. Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia
17. Fetal alloimmune thrombocytopenia: Consensus and controversy
18. Immune thrombocytopenic purpura in pregnancy
19. Perinatal management of idiopathic thrombocytopenic purpura in pregnancy: Risk factors for passive immune thrombocytopenia
20. Hematology
21. High dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease
22. ADCC (K cell) lysis of human erythrocytes sensitized with Rhesus alloantibodies. II. Investigation into the mechanism of lysis
23. Immunotherapy for recurrent miscarriage
24. The anti-inflammatory effect of an oral immunoglobulin (IgA-IgG) preparation and its possible relevance for the prevention of necrotising enterocolitis
25. The pathogenesis and prevention of Rh immunisation
26. Proceedings of the McMaster Rh conference
27. Anti-D administration in pregnancy for preventing rhesus alloimmunisation
28. Anti-D administration after childbirth for preventing rhesus alloimmunisation
29. Evolution of the immunologic functions of the mammary gland and the postnatal development of immunity
30. Breastmilk immunology
31. The immune system of human milk: Antimicrobial, antiinflammatory and immunomodulating properties
32. Human milk composition and function in the infant
33. Antiinflammatory properties of human milk
34. Tumor necrosis factor alpha in human milk
35. Effect of breast feeding on immune response to BCG vaccination
36. Free fatty acids and monoglycerides: Anti infective agents produced during the digestion of milk fat by the newborn
37. Effect of antiviral lipids, heat and freezing on the activity of viruses in human milk
38. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides
39. The role of milk derived antimicrobial lipids as antiviral and antibacterial agents
40. Antimicrobial lipids: Natural and synthetic fatty acids and monoglycerides
41. Lipids as host resistance factors of human milk
42. Cholate dependent killing of Giardia lamblia by human milk
43. Killing of Giardia lamblia by human milk is mediated by unsaturated fatty acids
44. Killing of Giardia lamblia by human milk lipases: An effect mediated by lipolysis of milk lipids
45. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops
46. Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with development of bronchopulmonary dysplasia
47. Tracheal aspiration cytology in neonates with respiratory distress: Histopathologic correlation
48. Differential cytokine mRNA expression by neonatal pulmonary cells
49. Cytologic evaluation of pulmonary effluent in neonates with respiratory distress syndrome and bronchopulmonary dysplasia
50. Newborn tracheal aspirate cytology classification during respiratory distress syndrome and bronchopulmonary dysplasia
51. Lung lavage with newborns with respiratory distress syndrome: Prolonged neutrophil influx is associated with bronchopulmonary dysplasia
52. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance
53. Infection, neutrophils, and hemopoeitic growth factors in the pathogenesis of neonatal chronic lung disease
54. Inflammatory mechanisms in neonatal chronic lung disease
55. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: A sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates
56. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia
57. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia
58. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant
59. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia
60. Short term dexamethasone therapy for bronchopulmonary dysplasia: Acute effects and 1-year follow-up
61. Randomised placebo controlled trial of a 42 day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants
62. Dexamethasone therapy in severe bronchopulmonary dysplasia
63. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants
64. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome, double blind, controlled study
65. Is chronic lung disease (CLD) in premature infants preventable?
66. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia
67. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: A randomized trial
68. Efficacy of early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity
69. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome
70. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants
71. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
72. Delayed (> 3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants
73. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: A systematic review of RCTs
74. Cromolyn sodium prophylaxis inhibits pulmonary pro-inflammatory cytokines in infants at high risk for bronchopulmonary dysplasia
75. The role of haemopoietic growth factors in neonatal neutropenia and infection
76. Effect of granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF) on neonatal neutrophil functions
77. Human IL-3 and GM-CSF act synergistically in stimulating hematopoeisis in primates
78. Synergistic factors for stem cell proliferation: Further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony stimulating factor
79. Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor
80. A randomised placebo controlled trial of recombinant granulocyte colony stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia
81. Treatment of alloimmune neutropenia with granulocyte colony stimulating factor
82. Effect of granulocyte colony-stimulating factor on preeclampsia-associated neonatal neutropenia
83. Administration of granulocyte colony-stimulating factor to neutropenic low birth weight infants of mothers with preeclampsia
84. Granulocyte colony stimulating factor treatment for neonatal neutropenia
85. A randomised, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early onset sepsis
86. 'Idiopathic neutropenia' in very low birth weight infants
87. Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: A meta-analysis
88. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia
89. The in vivo effect of recombinant human granulocyte colony-stimulating factor in neutropenic neonates with sepsis
90. UK multicentre prospective, randomised, double-blind, placebo-controlled trial of rh-GCSF (granulocyte colony stimulating factor) in neonatal sepsis
91. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with clinical diagnosis of early-onset sepsis
92. Granulocyte colony-stimulating factor serum and urinary concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony stimulating factor
93. Transplacental passage of recombinant human granulocyte colony stimulating factor in women with an imminent preterm delivery
94. A randomised, double-blind, placebo controlled pilot trial of recombinant granulocyte colony-stimulating factor administration in women prior to preterm delivery
95. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony stimulating factor in very low birthweight neonates: Significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils
96. Granulocyte-macrophage colony-stimulating factor in the treatment of neonates with neutropenia and sepsis
97. A randomised trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia
98. A double-blinded randomised placebo (P) controlled pilot study of rhGM-CSF in low birth weight neonates (LBWN). Preliminary results demonstrate significant reduction of nosocomial infections with rhGM-CSF
99. A randomised controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation
100. Impaired surface membrane expression of C3bi but not C3b receptors on neonatal neutrophils
101. Intravenous immunoglobulin in the treatment of neonatal sepsis: Therapeutic strategies and laboratory studies
102. Protective efficacy of a modified immune serum globulin in experimental group B streptococcal infections
103. Serum opsonic activity and peripheral neutrophil counts before and after exchange transfusion in infants with early onset Group B streptococcal septicemia
104. Opsonic and protective activity of immunoglobulin, modified immunoglobulin and serum against neonatal E. coli K1 infection
105. Enhancement of neonatal polymorphonuclear leucocyte (PMN) motility with adult fresh frozen plasma (FFP)
106. Hyper-immunoglobin E syndrome: Response to transfer factor and ascorbic acid therapy
107. A polyclonal human IgG preparation hyperimmune for type III Group B streptococcus: in vitro opsonophagolytic activity and efficacy in experimental models
108. Effect of intravenous immunoglobulin G on neutrophil kinetics during experimental Group B streptococcal infection in neonatal rats
109. Functional leucocyte administration protection against experimental neonatal infection
110. Neutrophil mobilisation induced by complement fragments during experimental Group B streptococcal infection
111. Blood transfusion in Group B streptococcal (GBS) infection
112. Defective mononuclear leucocyte chemotaxis: A previously unrecognised immune dysfunction. Studies in a patient with chronic mucocutaneous candidiasis
113. Polymorphonuclear leucocyte transfusion for the treatment of sepsis in the newborn infant
114. Granulocyte transfusions in neonates with infection, neutropenia and depletion of mature marrow neutrophils
115. Buffy coat transfusions in neutropenic neonates with presumed sepsis, a prospective randomized trial
116. Improved survival of newborns receiving leucocyte transfusions for sepsis
117. Role of circulating complement and polymorphonuclear leucocyte transfusion in the treatment and outcome in critically ill neonates with sepsis
118. Polymorphonuclear neutrophil transfusion in neonatal septicemia
119. Buffy coat transfusion in neonates with sepsis and neutrophil storage depletion
120. A controlled trial of prophylactic granulocyte transfusion during induction chemotherapy for acute myelogenous leukemia
121. Decreased bactericidal activity of leucocytes of stressed newborn infants
122. Acute leukemia and granulocyte transfusion: Fatal graft-versus-host reaction following transfusion of cells obtained from normal donors
123. Transmission of human immunodeficiency virus
124. Enhancement of neutrophil function for treatment of neonatal infections
125. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees
126. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy
127. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
128. Oxpentifylline in endotoxemia
129. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxyphylline
130. Pentoxyphylline suppression of tumor necrosis factor gene transcription
131. Effect of pentoxyphylline on the phagocytic activity, cAMP levels and superoxide anion production by monocytes and polymorphonuclear cells
132. Pentoxyphylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor
133. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor-alpha on neutrophil function by pentoxyphylline
134. Pentoxyphylline reduces injury to isolated lungs perfused with human neutrophils
135. Attenuation of tumor necrosis factor induced endothelial cell cytotoxicity and chemiluminescence
136. Effect of the immunomodulating agent, pentoxyphylline, in the treatment of sepsis in prematurely delivered infants: A placebo controlled, double-blind trial
137. Appraising the potential of pentoxyphylline in septic premies
138. Pentoxifylline
139. Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid interleukin 8 levels as markers of chronic lung disease in premature infants
140. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia
141. Infections in newborn infants and the potential for new prevention and treatment strategies
142. The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase
143. Effect of methylene blue on refractory neonatal hypotension
144. Naloxone and its use in neonatal septic shock
145. Therapy of shock with naloxone: A meta-analysis
146. Immunotherapy of endotoxemia and septicemia
147. Monoclonal antibody therapy for gram negative sepsis: Principles, applications, and controversies
148. Why sepsis trials fail
149. Treatment of sepsis: Past and future avenues
150. Adjunctive therapy in sepsis: A critical analysis of the clinical trial programme
151. Severe sepsis trials: Why have they failed?
152. Treating patients with severe sepsis
153. Why sepsis trials fail
154. Advances in the therapy for sepsis in children
155. Why immunomodulator therapies have not worked in sepsis
156. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
157. New strategies for combating sepsis: The magic bullets missed the mark... but the search continues
158. Clinical trials of mediator directed therapy in sepsis: What have we learned?
159. New insights into the pathogenesis of pulmonary inflammation in preterm infants